The assay developed tests for small molecules that block ELG1 function in response to DNA damage, which can kill cancer cells. Chemotherapeutic agents that induce DNA damage can be more effective when used with ELG1 inhibitors, expanding treatment options for cancer patients. The assay uses a quantitative high-throughput ELG1-luciferase reporter gene assay to monitor the suppression of luciferase activity. Is the molecule effective to this assay?